Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01891643 · OUTCOME

Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) · Source last updated 2021-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Percent of cells expressing CS1
Interval / dispersion
Full Range
Time frame
Time of progression (up to approximately 54 months from pre-treatment screening)

What was measured

CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at time of progression. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)

Analysis population: All treated participants with measurements available at time of progression.

Groups in this outcome

E-Ld Cohort

Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle

Ld Cohort

Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
E-Ld Cohort4
Ld Cohort1

Reported measurements

Source class 1
Values in Percent of cells expressing CS1 · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
E-Ld Cohort46.59Not reported0.099.1Not reported
Ld Cohort84.62Not reportedNANAOnly 1 participant analyzed
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.0
        upper Limit
        99.1
        value
        46.59
      2. comment
        Only 1 participant analyzed
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        84.62
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    2. group Id
      OG001
      value
      1
    units
    Participants
description
CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at time of progression. The following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)
dispersion Type
Full Range
groups
  1. description
    Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle
    id
    OG000
    title
    E-Ld Cohort
  2. description
    Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle
    id
    OG001
    title
    Ld Cohort
param Type
MEDIAN
population Description
All treated participants with measurements available at time of progression.
reporting Status
POSTED
time Frame
Time of progression (up to approximately 54 months from pre-treatment screening)
title
Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression
type
SECONDARY
unit Of Measure
Percent of cells expressing CS1

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice